The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA seeks U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).
Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.
- Duke Internal: DCI currently has this grant and will be applying for a renewal.
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): May 22, 2019
RFA-CA-19-008 Expiration Date May 23, 2019
Individual(s) designated as Program Director(s)/Principal Investigator(s) (PDs/PIs) are expected to be national and international leaders in cancer-related pharmacokinetic studies for early phase clinical trials of novel therapeutic agents and translational research.
Proposed investigators must be highly capable of inter- and trans-disciplinary team-based research with investigators involved in the design and conduct of clinical trials.
Application budget requests are limited to $320,000 (direct costs) per year.
Project period of 6 years should be requested.